Study: Alogliptin does not raise heart risk in diabetes

10/3/2013 |

The diabetes drug alogliptin did not appear to increase the odds of heart attack, stroke or cardiac death compared with placebo in type 2 diabetes patients with cardiovascular problems, a study in The New England Journal of Medicine revealed. Data on 5,380 patients showed 11.3% of those in the alogliptin arm died from heart problems or suffered a heart attack or stroke, compared with 11.8% of those who took a placebo.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC